Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer

Ekaterina Mostovenko, Yanhong Liu, E. Susan Amirian, Spiridon Tsavachidis, Georgina N. Armstrong, Melissa L. Bondy, Carol L. Nilsson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.

Original languageEnglish (US)
Pages (from-to)80-84
Number of pages5
JournalACS chemical neuroscience
Issue number1
StatePublished - Jan 17 2018
Externally publishedYes


  • GBM
  • Glioblastoma
  • drug target
  • molecular epidemiology
  • precision medicine
  • proteomic

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer'. Together they form a unique fingerprint.

Cite this